Trial Profile
A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Adverse reactions; First in man
- Sponsors Alnylam Pharmaceuticals
- 13 Sep 2021 Results of an analysis assessing the effect of Lumasiran on kidney stones and Nephrocalcinosis in patients with Primary Hyperoxaluria Type 1 from phase I/II, phase II OLE and two phase III studies (ILLUMINATE-A & ILLUMINATE-B) presented at the 116th Annual Meeting of the American Urological Association
- 31 Oct 2019 New results from the pediatric cohort were presented at the International Pediatric Nephrology Association (IPNA) 2019 Annual Meeting.
- 17 Jun 2019 According to the Alnylam Pharmaceuticals media release, results from this study will be presented at the 2019 Oxalosis & Hyperoxaluria (OHF) International Workshop being held in Boston, on June 21-22.